早期上皮性卵巢癌高危组患者术后单药顺铂化疗临床疗效探讨及其与血清激肽释放酶6表达的关系研究

Clinical investigation on relationship between the effect of cisplatin single agent chemotherapy for patients with early epithelial ovarian cancer in high risk group and the expression level of human kallikrein 6

目的探讨单药顺铂治疗早期上皮性卵巢癌高危组患者的临床疗效,及其与血清激肽释放酶6表达的关系。方法选取我院入院治疗的早期上皮性卵巢癌高危组患者40例,采用单药顺铂进行治疗。比较化疗前后患者血清中激肽释放酶6的表达差异,分析血清激肽释放酶6降低程度与临床疗效的关系。结果顺铂单药治疗总有效率为37.5%。其中,化疗开始时间与手术治疗间间隔<10d组有效率为50%,11～21d组有效率为42.9%,>21d组有效率为28.6%。>21d组患者的有效率明显低于其余两组(P<0.05)。15例(CR+PR)患者血清激肽释放酶6.05±0.57μg/L,显著低于25例(SD+PD)患者血清激肽释放酶4.38±0.79μg/L,两组比较差异有统计学意义(P<0.05)。结论单药顺铂化疗治疗早期上皮性卵巢癌高危组患者能达到较好的疗效,且血清激肽释放酶6的表达高低与临床疗效关系密切。

Objective To explore the relationship between the effect of csiplatin single agent chemotherapy for patients with early epithelial ovarian cancer in high risk group and the expression level of human kallikrein 6. Method 40 patients with early ovarian cancer in high risk group were enrolled and treated by cisplatin single agent chemotherapy. The expression level of kallikrein 6 was compared between pre and post chemotherapy. Results The total response rate of cisplatin single agent chemotherapy strategy was 37.5%. The response rate of the group whose time interval between chemotherapy start time and surgery treatment time was less than 10 days was 50%, that of 11～21d group was 42.9%. The response rate of 21d group was 28.6%, which is significantly lower than that of the other groups. The kallikrein 6 expression level of 15 patients （CR＋PR） was 6.05±0.57μg·L-1, which is significantly lower than 4.38±0.79μg·L-1 of 25 patients （SD＋PD）（P 0.05）. Conclusion The effect of cisplatin single agent chemotherapy strategy can achieve good result, which may correlated with the kallikrein 6 expression level.